Ascendis Pharma’s TransCon hGH Receives EC’s Approval for Pediatric Growth Hormone Deficiency

Published: Jan 14, 2022 | Tags: Ascendis Pharma, TransCon hGH, Lonapegsomatropin, European Commission, Pediatric Growth Hormone Deficiency, US FDA

Tempus Reports Initiation of an Open-Label P-II Study in Collaboration with GSK to Evaluate Zejula (niraparib) to Treat Advanced or Metastatic Solid Tumors

Published: Jan 14, 2022 | Tags: Tempus, P-II, Study, Collaboration, US FDA, PAVO study, GSK, Zejula, Niraparib, Solid Tumors, Germline, Somatic, PALB2 Mutation

Everest Medicines and Singapore's EDDC Enters into a Global Licensing Agreement to Develop and Commercialize EDDC’s 3CL Protease Inhibitors as COVID-19 Oral Antiviral Treatments Worldwide

Published: Jan 14, 2022 | Tags: Everest Medicines, Singapore, EDDC, Global Licensing Agreement, 3CL Protease Inhibitors, COVID-19, Oral Antiviral, SARS-CoV-2, EDDC-2214

RedHill Biopharma Reported New Data From a Prespecified Analysis of All Oral Opaganib's P-II/III Study in Severely Ill Hospitalized COVID-19 Patients.

Published: Jan 14, 2022 | Tags: RedHill Biopharma, Opaganib, COVID-19 Patients, PCR, Viral RNA clearance, COVID-19 pneumonia, Potential antiviral activity

BridgeBio and Amgen Entered into a Non-Exclusive Clinical Collaboration for BBP-398 in P-I/II Study for Advanced Solid Tumors

Published: Jan 14, 2022 | Tags: BridgeBio, Amgen, Non-Exclusive, Clinical Collaboration, BBP-398, Lumakras, KRAS G12C Mutation, Solid Tumors

Amgen and AstraZeneca Announced Tezspire’s (tezepelumab-ekko) Availability in the US to Treat Adult and Pediatric Patients with Severe Asthma

Published: Jan 14, 2022 | Tags: Amgen, AstraZeneca, Tezspire, Tezepelumab-ekko, Severe Asthma, US FDA, Orphan Drug Designation

Abbott Receives US FDA’s Clearance for EnSite X EP System to Treat Cardiac Arrhythmias

Published: Jan 13, 2022 | Tags: Abbott, US, FDA, Clearance, EnSite X EP System, Cardiac Arrhythmias

AstraZeneca Collaborates with Scorpion to Develop and Commercialize Precision Therapies for the Treatment of Cancer

Published: Jan 13, 2022 | Tags: AstraZeneca, Scorpion, Precision Therapies, Cancer

Mitsubishi Tanabe Pharma Reports US FDA Acceptance of NDA for Edaravone (MT-1186) for the Treatment of ALS

Published: Jan 13, 2022 | Tags: Mitsubishi Tanabe Pharma, US, FDA, NDA, Edaravone, MT-1186, ALS

Arrowhead Reports the First Patient Dosing in P-III (PALISADE) Study of ARO-APOC3 for the Treatment of Familial Chylomicronemia Syndrome

Published: Jan 13, 2022 | Tags: Arrowhead, P-III, PALISADE Study, ARO-APOC3, Familial Chylomicronemia Syndrome

Pfizer’s Reports Results of Prevnar 20 (pneumococcal 20-valent conjugate vaccine) in P-III Study for the Treatment of COVID-19

Published: Jan 13, 2022 | Tags: Pfizer, Prevnar 20, pneumococcal 20-valent conjugate vaccine, P-III Study, COVID-19

IMV Reports the First Patient Dosing in the P-IIb (VITALIZE) Study for MVP-S + Keytruda (pembrolizumab) for the Treatment of R/R DLBCL

Published: Jan 13, 2022 | Tags: IMV, P-IIb, VITALIZE Study, MVP-S, Keytruda, pembrolizumab, R/R DLBCL

Amryt Reports Results of Mycapssa in P-III (MPOWERED) Study for the Treatment of Acromegaly

Published: Jan 12, 2022 | Tags: Amryt, Mycapssa, P-III, MPOWERED Study, Acromegaly

Black Diamond Reports US FDA’s IND Clearance for BDTX-1535 to Treat Gliobastoma and Non-Small Cell Lung Cancer

Published: Jan 12, 2022 | Tags: Black Diamond, US, FDA, IND, BDTX-1535, Gliobastoma, Non-Small Cell Lung Cancer

Merck Expands its Collaboration with Aligos to Develop Oligonucleotide Therapies for the Treatment of NASH

Published: Jan 12, 2022 | Tags: Merck, Aligos, Oligonucleotide Therapies, NASH

Ascletis Reports the First Patient Dosing in the P-II Clinical Trial of ASC42 for the Treatment of Chronic Hepatitis B

Published: Jan 12, 2022 | Tags: Ascletis, P-II, Clinical Trial, ASC42, Chronic Hepatitis B

Sanofi Signs an Exclusive Collaboration and License Agreement with ABL to Develop and Commercialize ABL301 for Parkinson's Disease

Published: Jan 12, 2022 | Tags: Sanofi, ABL, ABL301, Parkinson's Disease

Pfizer Signs a Research Collaboration and License Agreement with Dren Bio to Advance Multiple Therapeutic Antibodies for Cancer

Published: Jan 12, 2022 | Tags: Pfizer, Dren Bio, Therapeutic Antibodies, Cancer

Moderna Collaborated with Carisma to Develop CAR-M Therapies for the Treatment of Cancer

Published: Jan 11, 2022 | Tags: Moderna, Carisma, CAR-M, Cancer

Merck Reports Results of Keytruda (pembrolizumab) in P-III (KEYNOTE-091) Trial as Adjuvant Treatment for Stage IB-IIIA NSCLC

Published: Jan 11, 2022 | Tags: Merck, Keytruda, pembrolizumab, P-III, KEYNOTE-091 Trial, Stage IB-IIIA NSCLC

Acadia Collaborated with Stoke to Develop and Commercialize RNA-Based Therapies for Rare Genetic Neurodevelopmental Diseases

Published: Jan 11, 2022 | Tags: Acadia, Stoke, RNA-Based Therapies, Rare Genetic Neurodevelopmental Diseases

Gilead Entered into a Clinical Trial Collaboration with Merck for Trodelvy (sacituzumab govitecan-hziy) + Keytruda (pembrolizumab) as 1L Treatment of Metastatic NSCLC

Published: Jan 11, 2022 | Tags: Gilead, Merck, Trodelvy, sacituzumab govitecan-hziy, Keytruda, pembrolizumab, Metastatic NSCLC

Pfizer Entered into an Exclusive Four-Year Research Collaboration with Beam to Boost In Vivo Base Editing Programs for Rare Diseases

Published: Jan 11, 2022 | Tags: Pfizer, Beam, In Vivo, Base Editing Programs, Rare Diseases

BMS Signs a Research Collaboration and License Agreement with Century for Allogeneic Cell Therapies to Treat Hematologic Malignancies and Solid Tumors

Published: Jan 11, 2022 | Tags: BMS, Century, Allogeneic Cell Therapies, Hematologic Malignancies, Solid Tumors

Bayer Entered into an Option Agreement with Mammoth Biosciences to Develop Novel Gene Editing Technology

Published: Jan 10, 2022 | Tags: Bayer, Mammoth Biosciences, Gene Editing Technology

Novartis and Molecular Partners Reports Results of Ensovibep (MP0420) in P-II (EMPATHY) Clinical Trial for the Treatment of COVID-19

Published: Jan 10, 2022 | Tags: Novartis, Molecular Partners, Ensovibep, MP0420, P-II, EMPATHY, Clinical Trial, COVID-19

Biohaven Entered into an Exclusive License and Research Agreement with KU Leuven to Develop and Commercialize BHV-2100 for Chronic Pain Disorders

Published: Jan 10, 2022 | Tags: Biohaven, KU Leuven, BHV-2100, Chronic Pain Disorders

Amgen’s Lumykras (sotorasib) Receives EC’s Approval for the Treatment of Non-Small Cell Lung Cancer

Published: Jan 10, 2022 | Tags: Amgen, Lumykras, sotorasib, EC, Approval, Non-Small Cell Lung Cancer

AbbVie Submits Application to US FDA and EMA for Rinvoq (upadacitinib) to Treat Non-Radiographic Axial Spondyloarthritis

Published: Jan 10, 2022 | Tags: AbbVie, US, FDA, EMA, Rinvoq, upadacitinib, Non-Radiographic Axial Spondyloarthritis

Regeneron Signs a License Agreement with Ultragenyx to Develop and Commercialize Evkeeza (evinacumab) for Homozygous Familial Hypercholesterolemia

Published: Jan 10, 2022 | Tags: Regeneron, Ultragenyx, Evkeeza, evinacumab, Homozygous Familial Hypercholesterolemia

Related Post: PharmaShots Weekly Snapshots (January 03 - 07, 2021)